Navigation Links
Resonant Medical Appoints New Vice President of Global Sales
Date:9/10/2007

MONTREAL, Sept. 10 /PRNewswire/ - Resonant Medical, the world leader in 3D ultrasound image-guided adaptive radiotherapy products, announced today that Mr. Joe Redfearn has joined the Company as Vice President Global Sales. This is a new position for Resonant Medical, and in this role, Mr. Redfearn will be responsible for the Company's global sales and customer support activities. He will also contribute to the expansion of the international distribution network.

"Mr. Redfearn brings to Resonant a track record of successful capital equipment sales and support management," said Steve Arless, Resonant's president & CEO. "His experience in the US and international marketplaces will help us achieve our bold goals for the coming years.

Mr. Redfearn joins the Company from Stereotaxis, where he was Vice-President of Capital Sales. He is a seasoned executive that has grown in the medical device industry for over 25 years, where he has worked for CryoCath Technologies, ThermoCardio Systems and CR Bard. "I'm excited to join the Resonant Medical Team and look forward to leading Resonant's efforts toward profitable revenue growth" commented Redfearn. "With new top management and proven product performance, Resonant is well-positioned for significant sales growth."

About Resonant Medical and Restitu(TM)

Resonant Medical Inc. is the world leader in 3D ultrasound image-guided radiotherapy products designed to improve treatment planning, verification and delivery. Recently, the company secured significant financing in order to develop and market Restitu(TM) add-on modules that will improve the quality of radiotherapy treatment for patients with breast, head & neck, cervix, bladder, and other soft tissue malignancies. These modules will compliment the previously released prostate module and Restitu(TM) platform, which are already in use in dozens of cancer clinics and university hospitals in North America.

The Restitu(TM) Platform accurately visualizes and corrects daily changes in tumor position, shape and size, thus ushering in a new era of 3D ultrasound (U/S) multimodality radiotherapy treatment planning and image guidance. Installed in CT-Sim rooms, Restitu U/S-Sim(TM) allows for better definition of planning tumor volumes with its patented IMPLICIT REGISTRATION(TM) technology that automatically fuses 3D U/S to CT data. With U/S-Sim, multimodality treatment planning has now been made possible and affordable for all clinics, with or without PET or MRI. Installed in treatment rooms, Restitu U/S-Guide(TM) allows for highly accurate patient position verification and alignment, with its proprietary MUTUAL REFERENCING(TM) technology that uses assisted segmentation for efficient and robust intramodality 3D U/S image-guidance.


'/>"/>
SOURCE Resonant Medical inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Check if your “Favourite medical web-site” is indulging in Quackey
2. Teens turning to Internet for medical queries
3. Ayurvedic Therapies Cashing In On Medical Tourism
4. Robots craft medical history
5. NBE to conduct test for medical students from abroad
6. Air pollution combined with greater medical needs
7. Indian Nationals with Foreign Medical Degrees can now practice in India
8. Children! Protecting them from medical mistakes
9. More information sought by patients on medical errors
10. SARS necessitates medical masks
11. Meditation Works Medically
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... 2017 , ... RawTrition now brings you BioEnergy which is a powder capsule ... , RawTrition is taking nutrients to the next level! The superfoods in ... raw form (unlike the synthetically made options that are on the market). , Founder ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... cream that’s the first in a new class of photodynamic cosmetics (PDC). , ... of skin, visibly reduce outward signs of aging, and minimize the appearance of ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... CEOs, CFOs and HR decision-makers are preparing for how his administration could impact ... will provide insight into what changes are most likely to make it through ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... targets, they rely on contracted partners to help with process innovation in drug ... combined drug formulation experience along with state-of-the-art analytical equipment in support of their ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... of predictive analytics to its patient care management module. Using this new feature, ... a patient has been initiated on continuous positive airway pressure (CPAP), oral, or ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... NEW YORK , April 19, 2017 /PRNewswire/ ... This report on the prostate cancer ... of the global market. Increasing prevalence of prostate ... as innovation in the development of new drugs ... hormone-refractory prostate cancer drug due to lesser side ...
(Date:4/19/2017)... April 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... biopharmaceutical company developing new treatments for cancer and ... of its previously announced underwritten public offering of ... public offering price of $2.00 per share, before ... expenses payable by Sorrento.  The net proceeds to ...
(Date:4/19/2017)... April 19, 2017  Novartis today announced the ... Heart, Lung, and Blood Institute (NHLBI) of the ... of patients with treatment-naïve severe aplastic anemia (SAA) ... with eltrombopag at the initiation of and concurrently ... evaluated three sequential treatment groups, or cohorts. Cohort ...
Breaking Medicine Technology: